Can-Fite BioPharma Ltd.
Namodenoson
hepatocellular carcinoma
Resolved
102days ago
Approval decision · Mar 27, 2026
What's at stake
A final FDA approval decision on Namodenoson for hepatocellular carcinoma is expected Mar 27, 2026.
Primary source
· SEC 6-K
verified 12h ago
“Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.”